Karyopharm Therapeutics Inc BOSTON Data Conference Call Transcript
Good afternoon. My name is Dilem, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics Phase III BOSTON Study Results Conference Call. (Operator Instructions) Please be advised that this call is being recorded at the company's request.
I would now like to turn the call over to Mr. Ian Karp, Karyopharm's Vice President, Investor and Public Relations. Please go ahead.
Great. Thanks. And thank you all for joining us on today's conference call to discuss the results from the Phase III BOSTON study presented this morning at ASCO 2020. This is Ian Karp, and I'm joined today by Dr. Michael Kauffman, Chief Executive Officer; Dr. Jatin Shah, Chief Medical Officer; and Mr. John Demaree, Chief Commercial Officer.
On the call today, Dr. Kauffman will provide some general thoughts about the Phase III BOSTON trial results, and then Dr. Shah will review the key findings from the study, which were presented for
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |